- TRADE NAMES: Arcapta Neohaler (Novartis); Onbrez Breezhaler (Novartis); Utibron Neohaler (Novartis)
- INDICATIONS: Long term, once-daily maintenance bronchodilator treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema
- CLASS: Beta-2 adrenergic agonist, Bronchodilator
- HALF-LIFE: 40–56 hours
- FDA APPROVAL DATE: 07/01/2011
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetazolamide, Adrenergics, Aminophylline, Arsenic, Corticosteroids, Diuretics, Dolasetron, Erythromycin, Ketoconazole, MAO inhibitors, Pazopanib, QT prolonging agents, Ritonavir, Steroids, Telavancin, Theophylline, Tricyclic antidepressants, Verapamil, Xanthine derivatives
Studies in asthma patients showed that long-acting beta2-adrenergic agonists may increase the risk of asthma-related death.
Contra-indicated in patients with asthma without use of a long-term asthma control medication.
Utibron Neohaler is indacaterol and glycopyrrolate.
ASTHMA-RELATED DEATH
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
DRUG REVIEW ARTICLE
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of Indacaterol in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
